Loading, Please Wait...
ROCHESTER, N.Y., May 15, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that two posters on its lead monoclonal antibody candidate, pepinemab (VX15/2503), will be presented at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held May 31 – June 4 in Chicago.
Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex, stated, “We are pleased to have two posters for presentation at this year’s ASCO meeting that highlight what we believe is the potential utility of our lead anti-SEMA4D therapeutic candidate, pepinemab, in combination with checkpoint inhibitors. We look forward to the presentation of updated data from these ongoing open-label studies.”
The abstracts for the posters will be available for review on the ASCO website at abstracts.asco.org and on the company’s Events and Presentations website beginning at 5:00 PM ET on May 15, 2019. The schedule and locations for the presentation of the posters at the ASCO annual meeting are summarized below.
|Title:||Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)|
|Date:||Saturday, June 1|
|Time:||8:00am – 11:00am CDT|
|Poster board #:||245|
|Collaborator:||Merck KGaA, Darmstadt, Germany|
|Title:||Pilot Integrated Biomarker Study of VX15/2503 in Combination with Ipilimumab and/or Nivolumab in Patients with Resectable Metastatic Melanoma|
|Date:||Monday, June 3|
|Time:||1:15pm – 4:15pm CDT|
|Poster board #:||169b|
|Collaborator:||Winship Cancer Institute of Emory University (Investigator Sponsored Clinical Trial)|
About Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based in Rochester, New York.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “potential,” “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements may involve substantial risks and uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab (VX15), and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in our Form 10-K dated March 13, 2019 and Form 10-Q dated May 15, 2019.
LifeSci Advisors, LLC